论文部分内容阅读
目的:研究探讨通脉胶囊用于治疗急性心肌梗塞(AMI)的临床疗效,并分析其对心功能造成的影响。方法:将2014年1月—2014年12月来我院进行诊治的120例急性心肌梗塞患者按随机分布表法分为对照组(60例)和观察组(60例)。对照组采用常规药物治疗,观察组采用常规药物+通脉胶囊治疗。分别在药物治疗前后测定患者体内心肌损伤指标CK-MB、LD、c Tn I、Mb;凝血指标PT、APTT、血纤维蛋白原以及心功能指标LVESD、LVEDD、LVESV、LVEDV、LVEF等。结果:经相关药物治疗后,观察组与对照组药物治疗后CK-MB、LD、c Tn I、Mb有明显降低,PT、APTT时间均延长,纤维蛋白原含量减少,LVESV、LVEDV均降低,LVEF均增高,有统计学差异(P<0.05)。且与对照组比较,观察组治疗后CK-MB、LD、c Tn I、Mb明显降低;PT、APTT时间明显延长,纤维蛋白原含量明显减少;LVESV、LVEDV明显降低,LVEF明显增高,差异具有统计学差异(均P<0.05)。结论:临床治疗急性心肌梗塞(AMI),在常规用药基础上加用通脉胶囊,抑制血栓形成,缩小心肌梗死面积,改善心功能,临床疗效显著。
Objective: To study the clinical efficacy of Tongmai capsule in the treatment of acute myocardial infarction (AMI) and analyze the influence of Tongmai capsule on cardiac function. Methods: A total of 120 acute myocardial infarction patients diagnosed and treated in our hospital from January 2014 to December 2014 were randomly divided into control group (60 cases) and observation group (60 cases). The control group was treated with conventional drugs, and the observation group was treated with routine drugs + Tongmai capsule. The indexes of myocardial injury such as CK-MB, LD, cTnI, Mb were measured before and after the drug treatment. The indexes of coagulation PT, APTT, fibrinogen, LVESD, LVEDD, LVESV, LVEDV and LVEF were measured. Results: After treatment with the relevant drugs, the levels of CK, MB, LD, cTnI and Mb in the observation group and the control group were significantly decreased, the PT and APTT time prolonged, the content of fibrinogen decreased, the LVESV and LVEDV decreased, LVEF increased, with statistical difference (P <0.05). Compared with the control group, the levels of CK-MB, LD, cTn I and Mb in the observation group were significantly decreased; the time of PT and APTT was prolonged and the content of fibrinogen was significantly decreased; LVESV and LVEDV were significantly decreased and LVEF was significantly increased Statistical difference (all P <0.05). Conclusion: Clinical treatment of acute myocardial infarction (AMI), on the basis of conventional medication with Tongmai capsule, inhibit thrombosis, reduce myocardial infarct size, improve cardiac function, clinical efficacy significantly.